There was initial resistance to Mullick’s appointment. “I had people hanging on the office door, saying: ‘So what is it that you do, exactly?’” she recalled. To win over sceptics, she focused on demonstrating impact, particularly through two major health projects addressing the reproductive health needs of girls, funded by the Gates Foundation and the US Centres for Disease Control and Prevention.
Mullick highlights a significant example of a product that underperformed: Implanon NXT, a long-acting subdermal contraceptive introduced in South Africa in 2014. While studies indicated its effectiveness, uptake plummeted after the initial launch. Mullick and her team were tasked with uncovering the issue, and they found that the early removal of the contraceptive was a major problem.
“For it to be effective, it needs to stay in the body for years, but the average time between insertion and removal was about eight months due to side effects. Misinformation also contributed; half of those interviewed couldn’t recall being informed about side effects, and a quarter had not been briefed on the product’s effectiveness,” she explained.
“The product was fine, but the programme lacked adaptability. Had implementation science been applied, we would have enhanced provider training, better prepared the community, improved counselling, and established monitoring systems to identify issues earlier,” Mullick added.
There is now greater awareness of implementation science, which Mullick describes as multidisciplinary. “You need service delivery models proven in real settings, community engagement, effective monitoring systems, and affordable products. Our market shaping team works with generic pharmaceutical companies to lower technology costs. Guidelines must also be in place; it’s a whole value chain,” she said.
Rees commended Mullick’s diplomacy and her ability to listen and adapt. Colleagues praised her calm demeanour and her capacity to recognise and nurture potential without micromanaging. When these compliments were relayed to her, Mullick remained humble. “We have many strong personalities across different portfolios, but it works because we share a uniting vision: to improve evidence-based access to technologies that enhance health, especially for underserved populations,” she concluded.